Literature DB >> 16552261

Nasal and paranasal sinus carcinoma: how can we continue to make progress?

Pavel Dulguerov1, Abdelkarim S Allal.   

Abstract

PURPOSE OF REVIEW: New developments in the nasal and paranasal sinus cancers are reviewed. RECENT
FINDINGS: In addition to woodworking, several risk factors for nasal and paranasal sinus cancers have been identified, most notably smoking. Progress in the differential diagnosis of small round cell nasal and paranasal sinus cancers allows the precise diagnosis of esthesioneuroblastoma. Despite recent improvements, T staging for ethmoid and nasal cavity needs refinement. An association of surgery and radiation therapy remains the best treatment modality. Major developments include endoscopic resection of nasal and paranasal sinus cancers, high-precision radiotherapy techniques such as intensity-modulated radiotherapy, and proton-beam radiotherapy. There is probably no role for chemotherapy in esthesioneuroblastoma. Although chemotherapy is important for aggressive neoplasms, its generalized use for nasal and paranasal sinus cancers awaits the application/development of newer drugs. These drugs might be applied locally since the majority of recurrences remain local.
SUMMARY: Progress in the treatment of nasal and paranasal sinus cancers could be achieved through better prevention and the developments of more selective treatments such as endoscopic resection, high-precision radiotherapy, and new chemotherapy drugs.

Entities:  

Mesh:

Year:  2006        PMID: 16552261     DOI: 10.1097/01.moo.0000193177.62074.fd

Source DB:  PubMed          Journal:  Curr Opin Otolaryngol Head Neck Surg        ISSN: 1068-9508            Impact factor:   2.064


  16 in total

1.  Salvage Treatment of Local Recurrence in Esthesioneuroblastoma: A Meta-analysis.

Authors:  Mitchell R Gore; Adam M Zanation
Journal:  Skull Base       Date:  2011-01

Review 2.  Imaging Characteristics of Olfactory Neuroblastoma (Esthesioneuroblastoma).

Authors:  Arthur B Dublin; Matthew Bobinski
Journal:  J Neurol Surg B Skull Base       Date:  2015-09-14

Review 3.  Multimodal Therapy for Sinonasal Malignancies: Updates and Review of Current Treatment.

Authors:  Mayur D Mody; Nabil F Saba
Journal:  Curr Treat Options Oncol       Date:  2020-01-16

4.  Management of sinonasal tumors: prognostic factors and outcomes: a 10 year experience at a tertiary care hospital.

Authors:  Maliha Kazi; Sohail Awan; Montasir Junaid; Sadaf Qadeer; Nabeel Humayun Hassan
Journal:  Indian J Otolaryngol Head Neck Surg       Date:  2013-04-07

5.  The importance of early diagnosis in patients with maxillary sinus carcinoma.

Authors:  Matthias Kreppel; Ali-Farid Safi; Martin Scheer; Hans-Joachim Nickenig; Joachim Zöller; Simon Preuss; Moritz Meyer; Daniel Rothamel; Timo Dreiseidler
Journal:  Eur Arch Otorhinolaryngol       Date:  2015-09-07       Impact factor: 2.503

6.  Neoadjuvant chemoradiation in squamous cell carcinoma of the maxillary sinus: a 26-year experience.

Authors:  Matthias Kreppel; Sarah Danscheid; Martin Scheer; Jan Christoffer Lüers; Hans Theodor Eich; Joachim E Zöller; Orlando Guntinas-Lichius; Dirk Beutner
Journal:  Chemother Res Pract       Date:  2012-09-29

7.  Frontal sinus cancer resection and reconstruction.

Authors:  Gurdeep Singh Mannu; Narayanan Gopalakrishna Iyer; Jatin Shah
Journal:  JRSM Short Rep       Date:  2011-01-13

Review 8.  Treatment monitoring of paranasal sinus tumors by magnetic resonance imaging.

Authors:  Davide Farina; Andrea Borghesi; Elisa Botturi; Marco Ravanelli; Roberto Maroldi
Journal:  Cancer Imaging       Date:  2010-08-13       Impact factor: 3.909

9.  Tumour suppressive microRNA-874 regulates novel cancer networks in maxillary sinus squamous cell carcinoma.

Authors:  N Nohata; T Hanazawa; N Kikkawa; D Sakurai; L Fujimura; T Chiyomaru; K Kawakami; H Yoshino; H Enokida; M Nakagawa; A Katayama; Y Harabuchi; Y Okamoto; N Seki
Journal:  Br J Cancer       Date:  2011-08-16       Impact factor: 7.640

10.  Dosimetric comparison between coplanar and non coplanar field radiotherapy for ethmoid sinus cancer.

Authors:  Antoine Serre; Katia Idri; Pascal Fenoglietto; Norbert Ailleres; Lore Santoro; Claire Lemanski; Renaud Garrel; Marc Makeieff; Ali Allaw; Jean-Bernard Dubois; David Azria
Journal:  Radiat Oncol       Date:  2007-09-18       Impact factor: 3.481

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.